SCHEMBL23266190

SCHEMBL23266190

COc1ccc(CCCCO[C@@H]2O[C@H](CO)[C@@H](O)[C@H](O)[C@H]2O)cc1

nearest known ligand 0.67

Predicted protein targets (top 10)

geneUniProtsupporting neighboursconfidence
▸ SLC5A1 P13866 4/20 0.56
▸ SLC5A2 P31639 4/20 0.56
▸ MAOB P27338 1/20 0.55
▸ MMP1 P03956 1/20 0.50
▸ MMP7 P09237 1/20 0.50
▸ MMP8 P22894 1/20 0.50
▸ MMP12 P39900 1/20 0.50
▸ MMP13 P45452 1/20 0.50
▸ NPC1 O15118 1/20 0.50
▸ RAB9A P51151 1/20 0.50

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL23266326 1.00 SLC5A1 (0.56) SLC5A1SLC5A2MAOBMMP1MMP7
SCHEMBL23266188 1.00 SLC5A1 (0.56) SLC5A1SLC5A2MAOBMMP1MMP7
SCHEMBL23266310 1.00 SLC5A1 (0.56) SLC5A1SLC5A2MAOBMMP1MMP7
SCHEMBL23350452 1.00 SLC5A1 (0.56) SLC5A1SLC5A2MAOBMMP1MMP7
SCHEMBL23266192 1.00 SLC5A1 (0.56) SLC5A1SLC5A2MAOBMMP1MMP7
SCHEMBL23266324 1.00 SLC5A1 (0.56) SLC5A1SLC5A2MAOBMMP1MMP7
SCHEMBL23266227 0.99 SLC5A1 (0.55) SLC5A1SLC5A2MAOBMMP1MMP7
SCHEMBL23266226 0.99 SLC5A1 (0.55) SLC5A1SLC5A2MAOBMMP1MMP7
SCHEMBL23266183 0.99 SLC5A1 (0.55) SLC5A1SLC5A2MAOBMMP1MMP7
SCHEMBL23266185 0.99 SLC5A1 (0.55) SLC5A1SLC5A2MAOBMMP1MMP7

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
CN-119424312-A External preparation of glycoside medicine for treating diabetic skin wound and preparation method thereof 上海和黄药业有限公司 2025-02-14 — — CN claimed
CN-119424312-A External preparation of glycoside medicine for treating diabetic skin wound and preparation method thereof 上海和黄药业有限公司 2025-02-14 — — CN disclosed
CN-118078842-A Glycoside medicine oral preparation for treating ischemic cerebral apoplexy in recovery period and preparation method thereof 上海和黄药业有限公司 2024-05-28 — — CN disclosed
CN-118078842-A Glycoside medicine oral preparation for treating ischemic cerebral apoplexy in recovery period and preparation method thereof 上海和黄药业有限公司 2024-05-28 — — CN disclosed
US-11325937-B2 Glycoside compound and preparation method therefor, composition, application, and intermediate SHANGHAI HUTCHISON PHARMACEUTICALS LIMITED (CN) 2022-05-10 — — US disclosed
WO-2021139621-A1 METHOD FOR PREPARING GLYCOSIDE COMPOUND 上海和黄药业有限公司 2021-07-15 — — WO disclosed
EP-3819303-A1 GLYCOSIDE COMPOUND AND PREPARATION METHOD THEREFOR, COMPOSITION, APPLICATION, AND INTERMEDIATE Shanghai Hutchison Pharmaceuticals Limited (CN) 2021-05-12 — — EP disclosed
US-20210115082-A1 GLYCOSIDE COMPOUND AND PREPARATION METHOD THEREFOR, COMPOSITION, APPLICATION, AND INTERMEDIATE SHANGHAI HUTCHISON PHARMACEUTICALS LIMITED (CN) 2021-04-22 — — US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-11325937-B2 Glycoside compound and preparation method therefor, composition, application, and intermediate VEGFA, FLT4, FLT1 SLC5A1 431/4885SLC5A2 897/4885MAOB 1432/4885
US-20210115082-A1 GLYCOSIDE COMPOUND AND PREPARATION METHOD THEREFOR, COMPOSITION, APPLICATION, AND INTERMEDIATE VEGFA, FLT4, FLT1 SLC5A1 431/4885SLC5A2 897/4885MAOB 1432/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.

Send feedback